Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck

医学 微小残留病 头颈部鳞状细胞癌 肿瘤科 头颈部癌 内科学 癌症 白血病
作者
Natasha Honoré,Cédric van Marcke,Rachel Galot,Raphaël Helaers,Jérôme Ambroise,Aline van Maanen,Antonella Mendola,Hajar Dahou,Étienne Marbaix,Pascal Van Eeckhout,E. Longton,Michèle Magremanne,Sandra Schmitz,Nisha Limaye,J-P. Machiels
出处
期刊:Annals of Oncology [Elsevier]
卷期号:34 (12): 1175-1186 被引量:8
标识
DOI:10.1016/j.annonc.2023.09.3102
摘要

Forty to fifty percent of patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) relapse despite multimodal treatment. Circulating tumor DNA (ctDNA) has the potential to detect minimal residual disease (MRD) after curative-intent therapy and to identify earlier which patients will progress. We developed a tumor-agnostic plasma ctDNA assay to detect MRD in unselected LA SCCHN with the aim of predicting progression-free survival (PFS) and overall survival without the need for tumor sequencing.A 26-gene next-generation sequencing panel was constructed that included the most frequently mutated genes in SCCHN and two HPV-16 genes. MRD was assessed in each patient through an in-house informatic workflow informed by somatic mutations identified in the corresponding pre-treatment plasma sample. The presence of MRD was defined as the detection of ctDNA in one plasma sample collected within 1-12 weeks of the end of curative treatment. The primary endpoint was the PFS rate at 2 years. At least 32 patients were planned for inclusion with the hypothesis that PFS at 2 years was >80% in MRD-negative patients and <30% in MRD-positive patients (α = 0.05, β = 0.9).We sequenced DNA from 116 plasma samples derived from 53 LA SCCHN patients who underwent curative-intent treatment. ctDNA was detected in 41/53 (77%) patients in the pre-treatment samples. Out of these 41 patients, 17 (41%) were MRD positive after treatment. The 2-year PFS rate was 23.53% (9.9% to 55.4%) and 86.6% (73.4% to 100%) in MRD-positive and MRD-negative patients, respectively (P < 0.05). Median survival was 28.37 months (14.30 months-not estimable) for MRD-positive patients and was not reached for the MRD-negative cohort (P = 0.011).Our ctDNA assay detects MRD in LA SCCHN and predicts disease progression and survival without the need for tumor sequencing, making this approach easily applicable in daily practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
拉拉霍霍发布了新的文献求助10
1秒前
2秒前
隐形曼青应助美丽的之双采纳,获得10
5秒前
Zkxxxx发布了新的文献求助30
5秒前
nnmm11完成签到 ,获得积分10
6秒前
6秒前
万能图书馆应助快乐蜗牛采纳,获得10
9秒前
可乐不加冰完成签到 ,获得积分10
9秒前
友好惜雪发布了新的文献求助10
12秒前
12秒前
12秒前
夏漆应助赵再戌采纳,获得20
12秒前
nnmm11关注了科研通微信公众号
13秒前
14秒前
陈金致应助喜欢搞科研采纳,获得10
16秒前
FashionBoy应助言叶采纳,获得10
16秒前
17秒前
xin发布了新的文献求助10
17秒前
17秒前
19秒前
炙热尔阳完成签到 ,获得积分10
21秒前
医学生Mavis完成签到,获得积分10
24秒前
san发布了新的文献求助10
24秒前
喻鞅完成签到,获得积分10
24秒前
25秒前
25秒前
28秒前
28秒前
liudw完成签到,获得积分10
28秒前
32秒前
言叶发布了新的文献求助10
32秒前
Jasper应助wbero采纳,获得10
33秒前
哇哈完成签到 ,获得积分10
35秒前
CodeCraft应助zwf123采纳,获得10
37秒前
JamesPei应助zwf123采纳,获得10
37秒前
37秒前
37秒前
DIKING完成签到,获得积分10
38秒前
40秒前
喜羊羊完成签到 ,获得积分10
40秒前
高分求助中
Востребованный временем 2500
The Three Stars Each: The Astrolabes and Related Texts 1500
Agenda-setting and journalistic translation: The New York Times in English, Spanish and Chinese 1000
Les Mantodea de Guyane 1000
Very-high-order BVD Schemes Using β-variable THINC Method 950
Field Guide to Insects of South Africa 660
Foucault's Technologies Another Way of Cutting Reality 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3391478
求助须知:如何正确求助?哪些是违规求助? 3002609
关于积分的说明 8804745
捐赠科研通 2689187
什么是DOI,文献DOI怎么找? 1472999
科研通“疑难数据库(出版商)”最低求助积分说明 681297
邀请新用户注册赠送积分活动 674184